Head of the Carreras Leukemia Center at Marburg University Hospital and vice-president of the José Carreras Leukämie Stiftung, Professor Dr. Andreas Neubauer, leads a trial with ruxolitinib on a COVID-19 patient with success and plans scientific study on the use of an immune inhibitor against this viral disease.

Researchers from the MDS Group of the Josep Carreras Leukaemia Research Institute and the Munich Leukemia Laboratory map the mutations that can ease and accelerate the diagnosis of Myelodysplastic/Myeloproliferative Neoplasms rare malignancies.

PROTEOBLOOD, a French-Spanish cooperative network for the analysis of proteinopathies and the development of individualized therapies in hematological cancers, begins thanks to the cofounding of Interreg POCTEFA.

Laurence Zitvogel and Guido Kroemer, from the Gustave Roussy Cancer Center, will give the next Distinguished Lectures of the Josep Carreras Institute, that will be held online as webinars on Friday 26th at 12:00 CEST.

Manel Esteller, Gerardo Ferrer and Margalida Rossello publish a review regarding the state of the art of epitranscriptomic research on blood cancers.

Every year the Josep Carreras Foundation celebrates the day of the Unstoppables in the Week Against Leukemia, a week full of activities for patients, families, and civil society. This year, due to COVID19, it will be held online from the 21st to the 28th of June.

Researchers from the Josep Carreras Research Institute prove that the preclinical implementation of Acute Myeloid Leukaemia immunotherapy, based on CD123-redirected CAR T-cells, affects hematopoiesis, blood cells production, and reconstitution.

The Lymphoma Translational Research Group is developing in vitro and in vivo assays to characterize new antineoplastic drugs against Diffuse Large Cell Lymphoma (DLCG), Mantle Cell Lymphoma (MCL) and Transformed Follicular Lymphoma (TFL), in the FIS project Nº PI18/01383 financed by the Instituto de Salud Carlos III.

The Myelodysplastic Syndrome group, directed by Francesc Solé, has published the chapter "Cytogenetics in the genomic era", within the monograph coordinated by Torsten Haferlach "Deciphering molecular genetics in malignant haemopathies."

The Barcelona Endothelium Team, led by Enric Carreras, publishes a case review linked to previous work to detect whether the cause of thrombotic microangiopathy in Multiple Myeloma patients treated with carfilzomib is due to activation of the complement pathway, a cause that can be inhibited with a drug already on the market.